MEPIVACAINE
Prostatic Cancer
Complexo Hospitalario Universitario de A CoruñaSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
514 Active assets in the Prostatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
PROPOFOL Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
Degarelix Bayer | Phase 4 | BBB |
AVOLVE Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
View all 50 →
Same molecule, other indications
MEPIVACAINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →